Publication

Home/Publication

Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine

Poster EUROoCS H. Le et al. EUROoCS 2020 Download the [...]

By |2020-07-10T17:23:17+02:00July 8th, 2020|Publication|Comments Off on Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
Read More

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster [...]

By |2020-06-22T18:32:23+02:00June 22nd, 2020|BT-001, BT-001, Invir.IO, Publication|Comments Off on BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Read More

Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download [...]

By |2020-03-22T17:47:45+01:00November 8th, 2019|Publication, TG1050|Comments Off on Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
Read More

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane M. Harper, et al. Gynecologic Oncology, April 2019 - [...]

By |2020-07-22T14:05:49+02:00April 18th, 2019|Publication, TG4001, TG4001|Comments Off on The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Read More
Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166 67405 Illkirch Graffenstaden Cedex - France | Phone: + 33 (0) 3 88 27 91 00 - Fax: + 33 (0) 3 88 27 91 11
© 2018 Transgene - All rights reserved
Legal Notice - Credits